- What is the recommended cervical-cancer screening for her now?
Answer: No further screening is necessary
When you encounter cervical cancer screening questions, the key distinction is whether the patient still has a cervix. This fundamentally changes screening recommendations.
This patient had a total abdominal hysterectomy, meaning her cervix was removed along with the uterus. Since cervical cancer screening aims to detect abnormal cells in the cervix, no cervix means no need for screening. Her history of normal Pap smears and absence of cervical dysplasia further supports discontinuing screening.
Choice A is correct because current guidelines state that women who've had total hysterectomy for benign conditions (like fibroids) with no history of high-grade cervical lesions should stop cervical cancer screening entirely.
Choice B is wrong because HPV testing and cytology are only meaningful when a cervix is present. These tests sample cervical cells, which this patient no longer has.
Choice C is incorrect for the same reason - Pap smears examine cervical cells. Without a cervix, there's nothing relevant to sample. Continuing Pap smears would be unnecessary and potentially harmful.
Choice D makes no sense because HPV vaccination prevents cervical cancer, but this patient has no cervix. Annual Pap smears would again be sampling non-existent cervical tissue.
Study tip: Always clarify whether a hysterectomy was "total" (cervix removed) or "subtotal/supracervical" (cervix remains). Total hysterectomy for benign disease = stop screening. If the cervix remains or if the hysterectomy was for malignancy, different rules apply.
- Which of the following is the most appropriate next step in this patient's management?
Answer: Referral to a gynecologic oncologist for exploratory laparotomy and surgical staging.
When you encounter a postmenopausal woman with abdominal bloating, early satiety, ascites (fluid wave), bilateral complex adnexal masses, and markedly elevated CA-125, you're dealing with a highly suspicious presentation for advanced ovarian cancer. The key principle here is that ovarian cancer requires specialized surgical expertise for both diagnosis and optimal treatment outcomes.
Referral to a gynecologic oncologist for exploratory laparotomy and surgical staging (C) is correct because ovarian cancer management demands subspecialty care from the outset. Gynecologic oncologists have the expertise to perform optimal cytoreductive surgery (debulking), proper staging procedures, and can immediately transition to treatment if cancer is confirmed. Studies consistently show better outcomes when gynecologic oncologists manage ovarian cancer cases from initial surgery.
Option A is inadequate because laparoscopic surgery cannot achieve the comprehensive staging and potential debulking needed for suspected advanced ovarian cancer. Option B represents a critical error—you should never biopsy a suspected ovarian malignancy percutaneously due to risk of tumor spillage and tract seeding, which can worsen prognosis and staging. Option D is premature since you need tissue diagnosis and surgical staging before initiating chemotherapy; neoadjuvant therapy is reserved for cases where optimal debulking isn't initially feasible.
Study tip: For USMLE Step 2, remember that suspected ovarian cancer always goes directly to gynecologic oncology—no exceptions. Never biopsy ovarian masses percutaneously, and always obtain tissue diagnosis through surgical means when malignancy is suspected.
- What is the most appropriate initial cervical-cancer screening schedule?
Answer: Perform a Pap smear now and repeat in 12 months
When you encounter cervical cancer screening questions involving HIV-positive patients, remember that HIV infection significantly increases HPV-related cancer risk, requiring more aggressive screening protocols regardless of age or CD4 count.
HIV-positive women need earlier and more frequent cervical cancer screening because immunosuppression increases their risk of persistent HPV infection and rapid progression to cervical cancer. The correct approach is to perform a Pap smear immediately upon HIV diagnosis and repeat annually (option A). This intensive schedule helps detect precancerous changes early when they're most treatable.
Option B represents the standard screening approach for average-risk women aged 30-65, using co-testing with 5-year intervals. However, HIV-positive patients require annual screening, not the extended intervals used for immunocompetent women. Option C is incorrect because HIV infection overrides age-based screening guidelines - even though her CD4 count of 480 cells/µL suggests relatively preserved immunity, HIV status alone mandates immediate screening. Option D is unnecessarily aggressive; while HIV increases cancer risk, it doesn't justify bypassing initial cytology screening to proceed directly to diagnostic procedures.
Key study tip: HIV-positive patients follow different screening schedules for multiple cancers, not just cervical. Remember that immunocompromised status always intensifies screening protocols - whether it's more frequent intervals, earlier initiation, or both. For the USMLE, when you see HIV in a screening question, think "more aggressive" regardless of CD4 count or viral load numbers.
- What is the most appropriate recommendation regarding prostate cancer screening for this patient?
Answer: Engage in shared decision-making about the risks and benefits of PSA testing.
For men aged 55 to 69, the USPSTF recommends that the decision to undergo PSA-based screening for prostate cancer should be an individual one. This patient is at higher risk due to his age, African American race, and family history. The most appropriate approach is to engage in shared decision-making, discussing the potential benefits (small reduction in mortality) and harms (false positives, overdiagnosis, complications of biopsy and treatment) of screening before ordering a PSA test.
- Which of the following is the most appropriate initial management step for this patient?
Answer: Measurement of serum tumor markers followed by radical inguinal orchiectomy.
When you encounter a young man with a painless, solid testicular mass, you're dealing with testicular cancer until proven otherwise. This demographic (20-40 years old) combined with the clinical presentation—painless enlargement, firm consistency, and ultrasound showing a solid intratesticular mass—creates a high suspicion for malignancy that demands immediate action.
The correct approach is B: measure serum tumor markers (AFP, β-hCG, LDH) followed by radical inguinal orchiectomy. Tumor markers help with staging, prognosis, and monitoring treatment response, while radical orchiectomy provides both definitive diagnosis and primary treatment. The inguinal approach is crucial because it allows complete removal of the testicle and spermatic cord while avoiding potential tumor seeding.
A is absolutely contraindicated. Transscrotal biopsy or aspiration risks seeding cancer cells into the scrotal lymphatics, potentially changing the cancer's natural drainage pattern and worsening prognosis.
C misses the mark entirely. Epididymo-orchitis typically presents with pain, fever, and inflammatory symptoms—none of which are present here. The solid, intratesticular location on ultrasound also argues against infection.
D represents dangerous delay. Testicular cancer can progress rapidly, and the clinical picture is already highly suggestive. A "wait and see" approach could allow metastatic spread and worsen outcomes.
Key takeaway: For USMLE Step 2, remember that painless testicular masses in young men equal cancer until proven otherwise. Never biopsy through the scrotum, and don't delay definitive surgical management when the clinical picture is clear.
- What is the most appropriate colorectal-cancer screening strategy for this patient?
Answer: Start colonoscopy now and repeat every 5 years
When you encounter colorectal cancer screening questions, focus on family history as a key risk stratification factor. Patients with a first-degree relative diagnosed with colorectal cancer need earlier and more intensive screening than the general population.
For this 35-year-old with a father diagnosed at age 45, current guidelines recommend starting colonoscopy at age 40 (10 years before the relative's diagnosis age) or at the current age if already past 40. Since he's 35, he should start screening now. The screening interval should be every 5 years due to his increased risk, making option A correct.
Option B is wrong because fecal immunochemical testing (FIT) is less sensitive than colonoscopy and inappropriate for high-risk patients. While FIT is acceptable for average-risk screening, patients with significant family history need the superior detection and therapeutic capability of colonoscopy.
Option C represents average-risk screening guidelines (start at 50, repeat every 10 years) and fails to account for his family history. This approach would miss the critical window where his increased genetic risk becomes relevant.
Option D suggests CT colonography, which while effective for detection, cannot remove polyps if found. Given his high-risk status, the gold standard of colonoscopy with immediate polypectomy capability is preferred over imaging-only methods.
Study tip: Remember the "10-year rule" for family history - start screening 10 years before the age when the relative was diagnosed, but not before age 40. High-risk patients always need colonoscopy, not alternative screening methods.
- In addition to adjuvant radiation therapy, which of the following is the most appropriate long-term therapy for this patient?
Answer: Anastrozole for at least five years to suppress estrogen synthesis.
When you encounter breast cancer treatment questions, focus on matching the therapy to the tumor's molecular characteristics and the patient's menopausal status. Hormone receptor-positive (HR+), HER2-negative breast cancer in postmenopausal women requires endocrine therapy as the cornerstone of treatment.
This patient has HR+/HER2- breast cancer, making her tumor dependent on estrogen for growth. Since she's postmenopausal, her ovaries no longer produce estrogen, and the primary source becomes peripheral conversion of androgens by the enzyme aromatase. Anastrozole, an aromatase inhibitor, blocks this conversion and is the preferred first-line endocrine therapy for postmenopausal women with HR+ breast cancer. The standard duration is at least five years, making option C correct.
Option A is wrong because while chemotherapy might be considered given the positive lymph node, tamoxifen would be suboptimal in a postmenopausal woman when aromatase inhibitors are superior. Option B is incorrect because trastuzumab and pertuzumab target HER2-positive cancers, but this tumor is HER2-negative, making these drugs ineffective and inappropriate. Option D is wrong because observation alone ignores the positive lymph node (even micrometastases) and the hormone receptor-positive status, both of which indicate need for systemic therapy.
Remember this pattern: For postmenopausal women with HR+ breast cancer, think aromatase inhibitors first. The patient's history of DVT actually supports avoiding tamoxifen (which increases thrombotic risk) and favoring anastrozole, which doesn't carry this risk.
- Which breast-cancer screening strategy is most appropriate for her current risk profile?
Answer: Annual contrast-enhanced breast MRI beginning now, with mammography at age 30
When you encounter questions about BRCA mutation carriers, remember that these patients have dramatically elevated breast cancer risk (up to 87% lifetime risk for BRCA1) and require intensive, early screening protocols that differ significantly from average-risk women.
For BRCA1 mutation carriers, current guidelines recommend starting annual breast MRI at age 25-30 (or 10 years earlier than the youngest affected family member). MRI is superior to mammography for detecting cancers in young, high-risk women because it's more sensitive in dense breast tissue and doesn't rely on architectural distortion that develops with age. Adding mammography starting at age 30 captures microcalcifications that MRI might miss, providing complementary detection methods.
Answer A is correct because it follows evidence-based guidelines: early MRI screening captures the peak risk period for BRCA1 carriers (often in their 30s-40s), while adding mammography at 30 provides comprehensive surveillance.
Answer B fails because mammography alone has poor sensitivity in young, dense breasts typical of BRCA carriers and misses the critical early detection window. Answer C is inadequate since self-examination has no proven mortality benefit and delays potentially life-saving early detection in this ultra-high-risk population. Answer D represents an extreme approach that, while effective for risk reduction, isn't the question's focus on screening strategy and may not align with the patient's preferences for breast preservation.
For USMLE Step 2, remember that BRCA carriers need intensified, early screening starting in their twenties—think "MRI first, mammography added later" for these high-risk patients.
- In addition to radiation therapy, which of the following is the most appropriate adjuvant systemic therapy for this patient?
Answer: Anastrozole
This patient has hormone receptor (HR)-positive, HER2-negative breast cancer. For postmenopausal women, an aromatase inhibitor (e.g., anastrozole, letrozole, exemestane) is the preferred adjuvant endocrine therapy as it has shown superior efficacy compared to tamoxifen. Tamoxifen is typically used for premenopausal women. Trastuzumab is an anti-HER2 therapy and is not indicated. Doxorubicin is a chemotherapy agent, which may or may not be indicated depending on other risk factors (e.g., recurrence score), but endocrine therapy is standard for all HR-positive tumors.
- According to current guidelines, which of the following is the most appropriate recommendation for colorectal cancer screening for this patient?
Answer: Colonoscopy now and every 10 years if normal
Major US guidelines (including the USPSTF and American Cancer Society) now recommend starting colorectal cancer screening for average-risk individuals at age 45. Colonoscopy every 10 years is a primary screening modality. While other options like annual FIT or flexible sigmoidoscopy are acceptable alternatives, initiating screening at age 45 is the current standard of care. Delaying screening until age 50 is based on outdated recommendations.
- Which of the following procedures is most appropriate to surgically stage the axilla?
Answer: Sentinel lymph node biopsy
For patients with early-stage invasive breast cancer and a clinically negative axilla (no palpable lymph nodes), sentinel lymph node biopsy (SLNB) is the standard procedure for staging. It accurately identifies whether the cancer has spread to the initial draining lymph nodes while avoiding the significant morbidity (e.g., lymphedema, nerve injury) associated with a full axillary lymph node dissection. Axillary dissection is reserved for patients with positive sentinel nodes (in some cases) or clinically positive nodes. FNA is used for suspicious nodes, not for staging a clinically negative axilla.
- In addition to a dermatologic follow-up, which of the following is the most appropriate next step in this patient's management?
Answer: Wide local excision with 1-cm margins and a sentinel lymph node biopsy.
When you encounter melanoma staging questions on Step 2, focus on the Breslow depth and presence of ulceration, as these determine both prognosis and management approach.
This patient has a T2a melanoma (Breslow depth 1.01-2.0 mm without ulceration). The key management principle is that melanomas >1.0 mm thick require both wide local excision and sentinel lymph node biopsy (SLNB) to properly stage the disease. The 1-cm margin is appropriate for lesions 1.01-2.0 mm thick, and SLNB is essential because nodal involvement significantly affects prognosis and treatment decisions.
Choice A is incorrect because observation alone is insufficient for T2 melanomas. While thin melanomas (<1.0 mm) might be managed with surveillance, this depth requires surgical intervention.
Choice B represents a common misconception. Adjuvant immunotherapy is reserved for high-risk melanomas (typically stage III with positive nodes or stage IV), not for early-stage disease without evidence of nodal involvement.
Choice C is wrong because radiation therapy has no role in primary melanoma management. Melanomas are relatively radioresistant, and surgical excision remains the gold standard for local control.
The correct answer is D because it addresses both local control (wide excision with appropriate margins) and staging (SLNB to detect occult nodal disease).
Study tip: Memorize the Breslow depth cutoffs and their corresponding margin requirements: <1.0 mm needs 1-cm margins (no SLNB), 1.0-2.0 mm needs 1-cm margins with SLNB, 2.0-4.0 mm needs 2-cm margins with SLNB, and >4.0 mm needs 2-cm margins with SLNB.
- Which of the following is the most appropriate surgical management?
Answer: Wide local excision with sentinel lymph-node biopsy
When you encounter a melanoma management question, focus on the tumor thickness (Breslow depth) and ulceration status, as these determine both staging and surgical approach.
This patient has a 1.4-mm thick, non-ulcerated melanoma, which classifies it as T2a (intermediate thickness: 1.01-2.0 mm without ulceration). For intermediate-thickness melanomas, the standard of care includes wide local excision with appropriate margins (typically 1-2 cm for this thickness) plus sentinel lymph node biopsy (SLNB). The SLNB is crucial here because intermediate-thickness melanomas have a significant risk of microscopic lymph node involvement (approximately 10-25%), and nodal status is the most important prognostic factor for staging and treatment decisions.
Option A is correct because it provides both adequate local control and critical staging information through SLNB.
Option B is wrong because it omits the essential SLNB, and adjuvant interferon-alpha therapy is no longer standard care—newer immunotherapies have largely replaced it.
Option C is incorrect because PET-CT scanning isn't indicated for staging intermediate-thickness melanomas without clinical evidence of metastatic disease. It's typically reserved for thicker lesions (>4 mm) or when regional/distant metastases are suspected.
Option D is wrong because surgery remains the primary treatment for localized melanoma. Systemic immunotherapy is reserved for metastatic disease or high-risk resected melanomas in the adjuvant setting.
Remember: For melanomas 1-4 mm thick, always consider SLNB unless contraindicated. The nodal status will guide further treatment decisions and provide essential prognostic information.
- What is the most appropriate screening recommendation for lung cancer in this patient?
Answer: Annual low-dose computed tomography of the chest
The US Preventive Services Task Force (USPSTF) recommends annual screening for lung cancer with low-dose computed tomography (LDCT) in adults aged 50 to 80 years who have a 20 pack-year smoking history and currently smoke or have quit within the past 15 years. This patient is 58 years old, has a 35-pack-year history, and quit 10 years ago, meeting all criteria for screening. Chest X-ray and sputum cytology have not been shown to reduce mortality and are not recommended for screening.
- Which recommendation is most appropriate?
Answer: Reassure her that no routine pancreatic-cancer screening is recommended for average-risk individuals
When you encounter questions about cancer screening, always consider whether the patient meets established criteria for high-risk populations. Pancreatic cancer screening is only recommended for very specific high-risk groups, not for the general population.
Option A is correct because this patient has average risk for pancreatic cancer. Current guidelines recommend screening only for individuals with strong family history (typically two or more first-degree relatives with pancreatic cancer), known genetic syndromes (like BRCA2, Lynch syndrome, or Peutz-Jeghers), or specific hereditary pancreatitis mutations. Her smoking history and new-onset diabetes, while concerning symptoms that warrant clinical attention, don't qualify her for routine screening protocols.
Option B is wrong because annual CT screening isn't recommended for average-risk individuals and would expose her to unnecessary radiation and potential false positives. Option C is incorrect because endoscopic ultrasound screening is reserved for high-risk patients meeting specific genetic or familial criteria - this intensive approach isn't justified for her risk profile. Option D is flawed because CA 19-9 has poor sensitivity and specificity for early pancreatic cancer detection and produces too many false positives in average-risk populations.
Her new-onset diabetes at age 55 could potentially be an early sign of pancreatic cancer, but this alone doesn't warrant screening - it warrants clinical evaluation if she develops other concerning symptoms like weight loss, abdominal pain, or jaundice.
Remember: Cancer screening recommendations are risk-stratified. Always identify whether patients meet high-risk criteria before recommending intensive screening protocols that aren't indicated for average-risk individuals.
- Which adjuvant therapy is most appropriate to improve disease-free survival?
Answer: Six months of oxaliplatin-based combination chemotherapy (eg, FOLFOX)
When you encounter colon cancer staging questions, focus on the TNM classification to determine appropriate adjuvant therapy. This patient has T3N1M0 disease - indicating tumor invasion through the muscularis propria (T3) with 1-3 regional lymph nodes involved (N1) and no distant metastases (M0). This represents Stage IIIB disease.
For Stage III colon cancer (any T with N1-2, M0), standard of care is adjuvant chemotherapy with an oxaliplatin-based regimen like FOLFOX (5-fluorouracil, leucovorin, oxaliplatin) for 6 months. This combination significantly improves disease-free and overall survival compared to surgery alone, with evidence showing approximately 20% reduction in recurrence risk.
Choice A is correct because oxaliplatin-based chemotherapy is the established standard for node-positive colon cancer. Choice B (observation alone) would be appropriate only for Stage I-II disease with favorable features, but this patient's positive lymph nodes mandate adjuvant treatment. Choice C (pelvic radiation) is used primarily for rectal cancer, not colon cancer, since colon cancer rarely benefits from radiation therapy due to bowel mobility and toxicity concerns. Choice D (cetuximab monotherapy) is incorrect because cetuximab is reserved for metastatic disease and requires KRAS/RAS wild-type status for efficacy.
Remember this key principle: node-positive colon cancer (Stage III) always requires adjuvant chemotherapy unless contraindicated. The presence of even one positive lymph node dramatically changes prognosis and treatment approach from observation to active systemic therapy.
- Which of the following is the most appropriate next step in management to guide the need for adjuvant chemotherapy?
Answer: Order a 21-gene recurrence-score assay on the resected tumor specimen
When managing early-stage breast cancer, the key decision point after surgery is determining which patients need chemotherapy versus endocrine therapy alone. For hormone receptor-positive, HER2-negative tumors like this one, genomic testing helps stratify risk and guide treatment decisions.
The 21-gene recurrence score assay (Oncotype DX) analyzes the expression of specific genes to predict both recurrence risk and chemotherapy benefit. For this patient with a T1 (1.2 cm), node-negative, hormone receptor-positive tumor, this test is specifically indicated to determine whether she needs chemotherapy or can be managed with endocrine therapy alone. The assay provides a recurrence score that categorizes patients into low, intermediate, or high-risk groups, directly informing treatment decisions.
Option B is premature because you haven't established that this patient needs chemotherapy. While she may benefit from it, the genomic testing should guide this decision rather than automatically starting aggressive treatment. Option C assumes she's low-risk without proper risk stratification - endocrine therapy alone may be appropriate, but only after confirming low recurrence risk through testing. Option D addresses radiation therapy, which is a separate decision from systemic therapy and doesn't help determine chemotherapy need.
For USMLE Step 2, remember that modern breast cancer management emphasizes personalized medicine. When you see a hormone receptor-positive, HER2-negative, node-negative breast cancer case, think genomic testing first before jumping to chemotherapy decisions. The 21-gene assay has become standard of care for precisely this clinical scenario.
- Which of the following is the most appropriate screening for cervical cancer at this visit?
Answer: Cervical cytology (Pap test) alone
Current guidelines recommend cervical cancer screening with cytology (Pap test) alone every 3 years for women aged 21-29. Since this patient's last normal Pap test was 3 years ago at age 25, she is due for screening. HPV co-testing and primary HPV testing are not recommended as primary screening strategies for women under age 30.
- Which of the following is the most appropriate next test for staging before determining resectability?
Answer: Positron emission tomography (PET)/CT scan
For a newly diagnosed, potentially resectable non-small cell lung cancer, a PET/CT scan is the most important staging investigation. It is used to assess for mediastinal lymph node involvement and distant metastatic disease (e.g., in the bones, liver, adrenal glands), which are crucial for determining operability and treatment planning. Brain MRI is also part of standard staging but PET/CT provides comprehensive systemic staging. Bone scan and abdominal ultrasound have been largely replaced by the more sensitive whole-body PET/CT for initial staging.
- Which of the following is the most appropriate next step in management?
Answer: Endoscopic ultrasound with fine-needle aspiration and initiation of neoadjuvant therapy.
When you encounter a pancreatic mass with vascular involvement, you're dealing with a question about resectability staging and appropriate surgical candidacy. The key detail here is that the mass "encases more than 180 degrees of the superior mesenteric artery" — this is the defining feature of locally advanced, borderline resectable pancreatic cancer.
The correct approach is B) Endoscopic ultrasound with fine-needle aspiration and initiation of neoadjuvant therapy. This patient has borderline resectable disease based on the degree of SMA encasement. Current guidelines recommend tissue diagnosis followed by neoadjuvant chemotherapy (and possibly radiation) to potentially downstage the tumor and improve surgical outcomes. EUS-FNA provides both staging information and tissue confirmation while being minimally invasive.
A is wrong because proceeding directly to surgery would be inappropriate given the extensive vascular involvement. The encasement makes this technically unresectable at presentation, and attempting immediate surgery would likely result in positive margins or inability to complete the resection.
C is premature — this patient has no evidence of metastatic disease and excellent performance status. Borderline resectable pancreatic cancer can potentially become resectable with neoadjuvant therapy, so palliative care isn't the appropriate initial approach.
D is unnecessarily invasive when EUS-FNA can provide the same diagnostic information with lower morbidity and better staging capabilities.
Study tip: Remember the vascular criteria for pancreatic cancer resectability. Greater than 180-degree encasement of the SMA or celiac axis defines borderline resectable disease, which requires neoadjuvant therapy before considering surgery.
